Palvella Therapeutics (PVLA) Assets Average (2014 - 2026)

Palvella Therapeutics (PVLA) has reported Assets Average for 13 consecutive years, with $161.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Assets Average rose 92.83% year-over-year to $161.7 million; the TTM figure through Mar 2026 stood at $161.7 million (up 92.83% YoY), while the FY2025 annual figure was $73.9 million, up 54.3% from the prior year.
• Assets Average advanced to $161.7 million in Q1 2026 per PVLA's latest filing, from $63.2 million in the prior quarter.
• Across five years, Assets Average topped out at $161.7 million in Q1 2026 and bottomed at $18.5 million in Q1 2024.
• Historically, Assets Average has averaged $78.5 million across 5 years, with a median of $76.6 million in 2025.
• Annual changes were most pronounced in 2024 — Assets Average sank 79.16% — and 2025, when it surged 352.62%.
• Palvella Therapeutics' Assets Average stood at $97.3 million in 2022, then slumped by 65.62% to $33.5 million in 2023, then jumped by 62.51% to $54.4 million in 2024, then gained by 16.31% to $63.2 million in 2025, then surged by 155.6% to $161.7 million in 2026.
• Business Quant data shows PVLA's Assets Average at $161.7 million in Q1 2026, $63.2 million in Q4 2025, and $70.3 million in Q3 2025.